Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

Laurent Martin, Darko Maric, Salam Idriss, Marine Delamare, Amandine Le Roy, Nada Maaziz, Amandine Caillaud, Karim Si-Tayeb, Florence Robriquet, Marion Lenglet, Lucie Erceau, Christine Bellanné-Chantelot, Isabelle Plo, Bernard Aral, Céline Garrec, Fabrice Airaud, Clara Gianfermi, Vincent Antunes, Anna Keppner, Sarah Mathilda Vincent, Alexis Desfontaine, Nina Modé, Fabien Laporte, Anne Gaignerie, Caroline Chariau, Isabelle Leray, Coline Rogue, Laurent David, Richard Redon, Stephane Bezieau, Lamisse Mansour, Frederic Galacteros, Thibault Maillet, Marlène Pasquet, Pierre Cougoul, Anne-Marie Nloga, Claude Gardin, Corinne Guitton, Viviane Dubruille, Vannina Giacobbi-Milet, Thierry Leblanc, Zuhre Kaya, Denis Semama, Chloe James, Serge Carillo, Marlène Ochmann, Anders Waage, Erwan Mortier, Mike Maillasson, Agnès Quéméner, Holger Cario, Radek C. Skoda, Yaël Zermati, David Hoogewijs, Alexandre Marchand, Francois Girodon, Betty Gardie

Blood (2024) 144 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2024-213000

Published: 2024

Journal Articles

JAK2 -V617F-Driven Myeloproliferative Neoplasms (MPN) Are Initiated By a Subset of HSCs Marked By High Expression of the Vwf-GFP Reporter Gene

Quentin Kimmerlin, Marc Usart, Tiago Fonseca, Hui Hao-Shen, Radek C. Skoda

Blood (2024) 144 (Supplement 1): 751.

https://doi.org/10.1182/blood-2024-206909

Published: 2024

Journal Articles

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2 -V617F–positive myeloproliferative neoplasms

Marc Usart, Jan Stetka, Damien Luque Paz, Nils Hansen, Quentin Kimmerlin, Tiago Almeida Fonseca, Melissa Lock, Lucia Kubovcakova, Riikka Karjalainen, Hui Hao-Shen, Anastasiya Börsch, Athimed El Taher, Jessica Schulz, Jean-Christophe Leroux, Stefan Dirnhofer, Radek C. Skoda

Blood (2024) 143 (24): 2490–2503.

https://doi.org/10.1182/blood.2023020270

Published: 2024

Includes: Supplemental data

Journal Articles

Cellular Barcoding of JAK2 -V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages

Marc Usart, Tiago Almeida, Julien Roux, Athimed El Taher, Riikka Karjalainen, Quentin Kimmerlin, Shivam Rai, Hui Hao-Shen, Radek C. Skoda

Blood (2023) 142 (Supplement 1): 859.

https://doi.org/10.1182/blood-2023-181695

Published: 2023

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Shivam Rai, Hui Hao-Shen, Stefan Dirnhofer, Julien Roux, Rajbharan Yadav, Anamarija Pfeiffer, Jakob Vowinckel, Audrey Arjomandi, Brian Higgins, Lyrialle Han, Kerstin Trunzer, Pontus Lundberg, Radek C. Skoda

Blood (2023) 142 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2023-186631

Published: 2023

Journal Articles

Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms

Blood (2023) 141 (17): 2127–2140.

https://doi.org/10.1182/blood.2022017976

Published: 2023

Includes: Supplemental data

Journal Articles

Genetic basis and molecular profiling in myeloproliferative neoplasms

Damien Luque Paz, Robert Kralovics, Radek C. Skoda

Blood (2023) 141 (16): 1909–1921.

https://doi.org/10.1182/blood.2022017578

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Disrupting the Socs2 -Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms

Marc Usart, Cédric B. Stoll, Riikka Karjalainen, Hui Hao-Shen, Radek C. Skoda

Blood (2022) 140 (Supplement 1): 9580–9581.

https://doi.org/10.1182/blood-2022-169232

Published: 2022

Journal Articles

Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2 -V617F Positive MPN with Loss of Dnmt3a

Melissa Lock, Damien Luque Paz, Nils Hansen, Tiago Almeida Fonseca, MARC Usart, Shivam Rai, Hui Hao-Shen, Gabriele Mild, Stephan Dirnhofer, Radek C. Skoda, Jan Stetka

Blood (2022) 140 (Supplement 1): 3876–3877.

https://doi.org/10.1182/blood-2022-167002

Published: 2022

Journal Articles

Exploring the Functional Role of an Alternative mRNA Transcript of the EPO Gene

Cédric B. Stoll, Marc Usart, Michal Remen, Jakub Zmajkovic, Radek C. Skoda

Blood (2022) 140 (Supplement 1): 2434–2435.

https://doi.org/10.1182/blood-2022-170133

Published: 2022

Journal Articles

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Shivam Rai, Jan Stetka, MARC Usart, Hui Hao-Shen, Young Park, Remie Houston, Anthony R. Martinez Benitez, Matthew Wereski, Emily Guzzardi, Sonali Persaud, Hailey Ramzan, Alan Futran, Charley Xu, Jeremy Greenwood, Sayan Mondal, Craig Masse, Ross L. Levine, Radek C. Skoda, Andrew Dunbar

Blood (2022) 140 (Supplement 1): 6722–6723.

https://doi.org/10.1182/blood-2022-162621

Published: 2022

Journal Articles

Inhibiting Glutamine Metabolism with CB-839 Reduces Erythrocytosis in MPN Mice

MARC Usart, Shivam Rai, Nils Hansen, Alexandre Guy, Jan Stetka, Hui Hao-Shen, Tata Nageswara Rao, Radek C. Skoda

Blood (2021) 138 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2021-150321

Published: 2021

Journal Articles

JAK2 -V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Tata Nageswara Rao, Nils Hansen, Jan Stetka, Damien Luque Paz, Milena Kalmer, Julian Hilfiker, Max Endele, Nouraiz Ahmed, Lucia Kubovcakova, Margareta Rybarikova, Hui Hao-Shen, Florian Geier, Christian Beisel, Stefan Dirnhofer, Timm Schroeder, Tim H. Brümmendorf, Dominik Wolf, Steffen Koschmieder, Radek C. Skoda

Blood (2021) 137 (16): 2139–2151.

https://doi.org/10.1182/blood.2020005563

Published: 2021

Includes: Supplemental data

Journal Articles

MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages

Ronny Nienhold, Peter Ashcroft, Jakub Zmajkovic, Shivam Rai, Tata Nageswara Rao, Beatrice Drexler, Sara C. Meyer, Pontus Lundberg, Jakob R. Passweg, Danijela Leković, Vladan Čokić, Sebastian Bonhoeffer, Radek C. Skoda

Blood (2020) 136 (22): 2591–2595.

https://doi.org/10.1182/blood.2019002943

Published: 2020

Includes: Supplemental data

Journal Articles

Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2 -V617F Mouse Model

Jan Stetka, Nils Hansen, Lucia Kubovcakova, Hui Hao-Shen, Stefan Dirnhofer, Radek C. Skoda

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140548

Published: 2020

Journal Articles

Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation

Steffen Boettcher, C. Matthias Wilk, Jochen Singer, Fabian Beier, Elodie Burcklen, Christian Beisel, Monica S. Ventura Ferreira, Elise Gourri, Christoph Gassner, Beat M. Frey, Urs Schanz, Radek C. Skoda, Benjamin L. Ebert, Tim H. Brummendorf, Niko Beerenwinkel, Markus G. Manz

Blood (2020) 135 (18): 1548–1559.

https://doi.org/10.1182/blood.2019003079

Published: 2020

Includes: Supplemental data

Journal Articles

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Blood (2019) 134 (21): 1832–1846.

https://doi.org/10.1182/blood.2019000162

Published: 2019

Includes: Supplemental data

Journal Articles

IL-1β Secreted from Mutant Cells Carrying JAK2- V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression

Shivam Rai, Nils Hansen, Hui Hao-Shen, Stefan Dirnhofer, Nageswara Rao Tata, Radek C. Skoda

Blood (2019) 134 (Supplement_1): 307.

https://doi.org/10.1182/blood-2019-129800

Published: 2019

NARROW

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

JAK2 -V617F-Driven Myeloproliferative Neoplasms (MPN) Are Initiated By a Subset of HSCs Marked By High Expression of the Vwf-GFP Reporter Gene

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2 -V617F–positive myeloproliferative neoplasms

Cellular Barcoding of JAK2 -V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms

Genetic basis and molecular profiling in myeloproliferative neoplasms

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Disrupting the Socs2 -Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms

Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2 -V617F Positive MPN with Loss of Dnmt3a

Exploring the Functional Role of an Alternative mRNA Transcript of the EPO Gene

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Inhibiting Glutamine Metabolism with CB-839 Reduces Erythrocytosis in MPN Mice

JAK2 -V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages

Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2 -V617F Mouse Model

Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

IL-1β Secreted from Mutant Cells Carrying JAK2- V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only